menu
    • menu

    Company profile for Quallent Pharmaceuticals

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2021, Quallent Pharmaceuticals is dedicated to enhancing quality consistency and stability in the global pharmaceutical supply chain. Functioning as a private-label pharmaceutical distributor, Quallent collaborates with FDA-approved manufacturers to source select pharmaceuticals. This partnership ensures pharmacies can offer their patients safe, affordable, and uninterrupted access to medication.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Quallent PharmaceuticalsCaymanIslands Flag
    Country
    Country
    Cayman Islands
    Address
    Address
    P.O. Box 30997 Grand Cayman
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.quallentpharmaceuticals.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Boehringer Ingelheim Expands Access to Adalimumab-Adbm Injection for Humira

    Details:

    Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent, continuing the commercialization of Boehringer Ingelheim-labeled Cyltezo.


    Lead Product(s): Adalimumab

    Therapeutic Area: Immunology Brand Name: Cyltezo

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Recipient: Boehringer Ingelheim GmbH

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 13, 2024

    blank

    01

    Quallent Pharmaceuticals

    Cayman Islands
    arrow
    IPhEB Russia
    Not Confirmed

    Quallent Pharmaceuticals

    Cayman Islands
    arrow
    IPhEB Russia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adalimumab

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Recipient : Boehringer Ingelheim GmbH

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Boehringer Ingelheim Expands Access to Adalimumab-Adbm Injection for Humira

    Details : Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent, continuing the commercialization of Boehringer Ingelheim-labeled Cyltezo.

    Product Name : Cyltezo

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    May 13, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    US Commercialization Deal with Quallent Aims to Reduce Patient Costs

    Details:

    Alvotech will manufacture its high-concentration interchangeable biosimilar, AVT02, a monoclonal antibody and that has been approved as a biosimilar to Humira (adalimumab) for Quallent.


    Lead Product(s): Adalimumab

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Alvotech

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 30, 2024

    blank

    02

    Quallent Pharmaceuticals

    Cayman Islands
    arrow
    IPhEB Russia
    Not Confirmed

    Quallent Pharmaceuticals

    Cayman Islands
    arrow
    IPhEB Russia
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adalimumab

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Alvotech

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    US Commercialization Deal with Quallent Aims to Reduce Patient Costs

    Details : Alvotech will manufacture its high-concentration interchangeable biosimilar, AVT02, a monoclonal antibody and that has been approved as a biosimilar to Humira (adalimumab) for Quallent.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    April 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search